Tesis Biosciences has revolutionized the way we identify genetic mutations associated with Covid-19 risk. Their groundbreaking new test utilizes targeted genetic sequencing to pinpoint the genetic mutations that put individuals at the greatest risk of contracting the virus. This revolutionary development has the potential to save countless lives.
Tesis Biosciences’ Chief Research Officer, Divyen H. Patel, Ph.D., believes that widespread use of COVID-19 tests could save hundreds of thousands of lives and significantly reduce the severity of the virus in those infected. These tests are key to early and aggressive treatment, as well as providing individuals with the knowledge they need to take precautions against contracting the virus. The potential of these tests is enormous and could make a huge difference in the fight against COVID-19.
Our new test is a revolutionary breakthrough in our fight against Covid-19, utilizing data from over 50 studies conducted by scientists from around the world. This groundbreaking advancement gives us a better understanding of why some people are more vulnerable to the virus than others, making it an invaluable tool in our effort to control and mitigate the disease.
With Covid-19 having now taken the lives of nearly seven million people worldwide, and an alarming 1.12 million in the United States, the search for answers as to why some fare much worse than others continues.
While comorbidities and underlying health conditions are thought to be contributing factors, the mystery deepens as to why those deemed not at risk can still suffer severe symptoms or even long Covid, with symptoms persisting for years. With over 765 million confirmed cases, it is clear that no one is immune to this virus and its devastating effects.
Tesis has taken a groundbreaking approach to uncovering the mysteries of Covid-19, by performing a comprehensive genome-wide association study on over 3.2 billion base pairs of DNA. This study has identified approximately 60 single nucleotide polymorphisms (SNPs) associated with a higher risk of death and severe illness from Covid-19.
Even more remarkable, Tesis has identified a subset of even more specific SNPs that, when all present, can predict an increased risk of severe outcomes in those infected with the virus.
After years of painstaking research, Tesis has discovered a range of mutations that could be present in up to 1-3% of the population. Although the exact role of these mutations in relation to Covid-19 infections is still unclear, they are all linked to genes that are involved in the body’s initial response to an infection.
Experts suggest that dysfunction in these genes could trigger an over-exaggerated immune response known as “cytokine storm” resulting in excessive inflammation and, in extreme cases, even death.
The Covid-19 virus is continuously mutating, and with the emergence of new variants, it’s essential to identify those most vulnerable to its worst outcomes. Dr. Patel and his team have developed a test to do just that – without even knowing the exact relationship between the mutations and a severe Covid-19 response, the test can detect and protect those at the highest risk.
Regular screening of the population using this test should be a priority, enabling those at risk to take necessary steps to avoid the disease and seek immediate treatment if needed.
Tesis is taking bold steps to ensure its unique assay is protected and accessible to the public. The company is filing for patent protection, then taking the extra step to expedite the approval process with the FDA. If all goes according to plan, the test could be granted approval by the summer.
About Tesis Biosciences
Tesis Biosciences is transforming medicine with its groundbreaking genetically integrated medical platform. Our mission is to help physicians, hospitals, and researchers make breakthroughs in the treatment and management of major chronic conditions such as heart and lung disease, and cancer.
Through advanced genetic testing, Tesis enables healthcare providers and physicians to create individualized care plans tailored to the specific needs of each patient. We also make it easy for medical device and pharmaceutical companies to bring new products to market, thanks to our robust repository of genetic data and research. With Tesis, we’re revolutionizing the way treatments are delivered and helping to create healthier, more resilient futures for all.